Immuno-oncology Drugs Market, Immuno-oncology Drugs Market PDF Format CMI22

Immuno-oncology Drugs Market Market -Size, Share, Outlook,
and Opportunity Analysis, 2018–2026
Immuno-oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors,
Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and
CAR-T Cell Therapy), by Cancer Type (Non-Small Cell Lung Cancer, Acute
Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian
Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and
Head & Neck Cancers), and by Region - Global Trends, and Forecast till 2025
Immuno-oncology Drugs Market
Natural immunity system holds superior potential to specifcally target and destruct
tumors while avoiding harm to the normal healthy tissue along with long term memory
to prevent cancer recurrence. Immuno-oncology research has supported the fact that
immunity system can efectively identify tumors and can stop or control long term
growth of the same through immunosurveillance. However, cancer progression leads to
suppression of immunity systems natural functioning wherein immune-oncology
therapies play an important role. Advent of innovative immune-oncology therapies such
as immune-checkpoint inhibitors, therapeutic cancer vaccines, and CAR-T therapies has
spurred leading organizations to actively invest into research and development.
However, high costs associated with therapy is restraining growth of the immuno-
oncology drugs market.
Download PDF Brochure of Market Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1271
Market Dynamics
Global Immuno-oncology drugs market is driven by factors such as increasing prevalence of
cancer, active research and development by leading manufacturers through collaborations and
individual research, and robust pipeline. According to World Health Organization (WHO), cancer
is one of the major non-communicable diseases and the second-leading cause of death
worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were